31May

Novel AKT inhibitor fails to demonstrate a difference in the primary outcome of PFS: Results from phase II ProCAID trial

ProCAID: A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castrationresistant prostate cancer (mCRPC).


Abstract Number : 5520

Abstract Type : Poster Discussion Session

Indication : Metastatic Castration Resistant Prostate Cancer

Intervention : Capivasertib (C) plus docetaxel and prednisolone (DP)

Company : Cancer Research UK, Pharmaceutical/Biotech Company

Technology : Small Molecule


Result:

150 patients were randomised to 01/2019. Median follow up 16.77 months (IQR 12.0-26.5). PFS and OS by ITT and B status, are shown in the table (NR, not reached; CI confidence interval). Grade 3–4 adverse events (AE) were equally common between arms (62.2%). The most common AEs were diarrhoea, fatigue and nausea.


Conclusion:

Adding C to DP did not extend PFS. The OS secondary endpoint was significantly increased. PFS and OS results were consistent irrespective of PI3K/AKT/PTEN pathway activation status.


Commentary:

Adding capivasertib to docetaxel and prednisolone chemotherapy did not extend PFS in mCRPC patients. However, the OS secondary endpoint was significantly increased.


Refer to Metastatic Castration Resistant Prostate Cancer Market report for detailed Insights.